|
Pyoderma
Gangrenosum
Pyoderma gangernosum (PG) is a rare destructive inflammatory skin
disease that may start either in the absence of any underlying
disorder (idiopathic PG) or in association with systemic disease.
Common disease associations include ulcerative colitis and Crohn’s
disease, myeloid leukemia, IgA gammopathy and Takayasu arteritis.
Less common and rare disease associations include multiple myeloma,
rheumatoid arthritis, Wegener’s granulomatosis and systemic lupus
erythematosus (Olson, 1971) and Behcet’s disease.
Clinical
manifestations:

The
salient feature of PG is an ulcer with a raised inflammatory border
and a boggy necrotic base.
It
starts as a deep seated painful nodule or as a superficial
hemorrhagic pustule either de novo or after minimal trauma.
Rarely,
PG may start in the subcutaneous fat, presenting as an extremely
painful suppurative panniculitis. Breakdown of the lesion and the
centrifugal spread of the resulting ulcer will eventually reveal the
true nature of the process.
The
ulcerating lesions discharge a purulent and hemorrhagic exudate; the
irregular crenated border is elevated and is dusky red or purplish;
it is undermined, soggy, and often perforated so that pressure
releases pus both into the ulcer and through these openings.
Multiple lesions arising simultaneously or consecutively in
different parts of the body also occur.
Lesions
are usually solitary but may arise in clusters, which then coalesce
to form multi-centric irregular ulcerations.
Superficial ulcers may be confined to the dermis, but they often
extend to the fat and even down to the fascia.
PG may
occur at any age.
PG lesions are
almost invariably painful.
Any
area of the body may be involved. Although mucous membranes are
usually spared, aphthous lesions may occur in the oral mucosa;
massive ulcerative involvement of the oral cavity, larynx and
pharynx, vulva and eyes have occasionally been observed.
A halo
of bright erythema surrounds the margin of an advancing ulceration
which may expand rapidly in one direction and more slowly in
another, so that a serpignous configuration results.
Peripheral growth results from the burrowing extension of undermined
margin or from new hemorrhagic pustules arising on the border. The
base of such an ulcer is partially covered with necrotic material
and partially studded with small abscesses.
The
clinical course may present two patterns:
Explosive onset and rapid spread of lesions: this type is
characterized by pain, toxicity and fever, hemorrhagic blisters and
suppuration, extensive necrosis and soggy ulcer margins with a
highly inflammatory halo.
Indolent and slow form: exhibits massive granulation within the
ulcer from the onset, crusting and even hyperkeratosis at the
margins. It spreads slowly grazing over large areas of the body for
months and is characterized by spontaneous regression and healing in
one area and progression in another. In both forms, healing occurs
spontaneously at some time during the disease process resulting in
thin atrophic usually cribriform scars.
Laboratory findings:
There
are no specific diagnostic laboratory findings.
A high
ESR, leucocytosis and elevated CRP are invariably present. There may
be anemia and low serum iron.
Pathology:
The
neutrophil is the cytologic hallmark of the PG. Indeed PG responds
to sulfa drugs, which have an anti-neutrophilic action and PG has
been observed to occur as a side effect of treatment with
granulocyte-macrophage colony stimulating factor (GM-CSF) (Johnson
and Grimwood, 1994).
Histologic features are not diagnostic. They encompass edema,
neutrophilic infiltration, thrombosis, necrosis and abscess
formation that eventually regress with prominent fibroplasias (Harwitz
and Haseman, 1993).
Treatment of PG:
Idiopathic PG is treated with systemic corticosteroids, sulfa drugs
(as dapsone, sulfasalazine), cyclosporine, clofazimine. Adjunctive
topical treatments as intra-lesional steroids and topical
cyclosporine have been tried. However, in patients with an
underlying disease who happen to be the type of patients we are
likely to encounter in rheumatologic practice, therapy should be
directed primarily to the cause and not only (or even not at all) to
PG.
|